Invasive aspergillosis causes approximately 30% of invasive fungal infections in patients treated for cancer (11) . Until 1990 only one drug was available for the treatment of invasive Aspergillus disease, amphotericin B, which must be given intravenously and which has a number of serious toxicities. In 1990 itraconazole (ITZ) capsules became available and Aspergillus species were included in the spectrum of activity of the drug, although the drug was mainly used in the prophylactic setting due to poor bioavailability (11) . Ten years later an intravenous formulation of ITZ became available and allowed the drug to be used for the empirical or preemptive treatment of high-risk patients. With the registration of voriconazole and caspofungin, the arsenal of available drugs has increased further. However, despite antifungal therapy, the rate of mortality in patients with invasive aspergillosis remains very high, and clearly, new therapeutic approaches are needed. Combination therapy is one approach that can be used to improve the efficacy of antimicrobial therapy for difficult-to-treat infections, such as human immunodeficiency virus and mycobacterial infections. By analogy, the combination of ITZ with other compounds could represent a possible approach for the treatment of patients with invasive aspergillosis or patients infected with strains with reduced susceptibilities to antifungal agents. Resistance to antifungal azoles has been studied in yeasts and molds, especially Aspergillus. Resistance mechanisms include changes in the cellular azole content (an altered uptake or efflux mechanism), mutations in sterol desaturation during ergosterol biosynthesis, and mutations in or elevated levels of 14␣-demethylase (12, 42) . The recent discovery of drug effluxmediated resistance mechanisms in yeasts and Aspergillus opens new therapeutic concepts. It has been recognized that Candida albicans and Aspergillus nidulans express multidrug efflux transporter (MET) genes belonging to different classes, i.e., the ATP-binding cassette (ABC) transporters and the major facilitators (13, 48) . The expression of these genes and their targeted deletion determine the level of azole resistance.
In this study we investigated the in vitro interactions between ITZ and different nonantimicrobial membrane-active compounds against clinical ITZ-resistant (ITZ-R) and ITZsusceptible (ITZ-S) strains using four different drug interaction models.
Inoculum preparation. Conidia of the isolates were obtained from fresh cultures for the preparation of each inoculum. Spores were collected with a cotton stick and suspended in sterile water. After the heavy particles were allowed to settle, the turbidities of the supernatants were measured spectrophotometrically (Spectronic 20D; Milton Roy, Rochester, N.Y.) at 530 nm, the transmission was adjusted to 80 to 82%, and the supernatants were diluted to obtain a final inoculum of 0.4 ϫ 10 4 to 5 ϫ 10 4 CFU/ml. The inoculum size was verified by determination of the number of viable CFU after serial dilutions of the inoculum were plated onto Sabouraud dextrose agar.
Drugs used. All solutions were prepared ex novo with powders from the same lot. The drugs used in this study were ITZ (Janssen-Cilag, Tilburg, The Netherlands) and amiloride (AML), amiodarone (AMD), fluphenazine (FLU), lansoprazole (LAN), lidocaine (LID), nifedipine (NIF), and verapamil (VER), all from Sigma-Aldrich Chemie GmbH, Steinheim, Germany. The final concentrations of the drugs ranged from 0.03 to 16 g/ml for ITZ, 0.13 to 8 g/ml for AMD and AML, 1.25 to 80 g/ml for FLU and NIF, 0.6 to 40 g/ml for LAN, 0.25 to 16 g/ml for LID, and 10 to 640 g/ml for VER. All drugs were dissolved in dimethyl sulfoxide as the solvent. The concentrations of the membrane-active drugs were chosen to be within the range achievable in human plasma and were also those used in previous studies (1-3, 9, 17, 22, 31, 32, 38) .
MICs. MICs were determined by a broth microdilution method described in National Committee for Clinical Laboratory Standards (NCCLS) guidelines (M-38A) (43) .
The drug dilutions were made in RPMI 1640 medium (with L-glutamine, without bicarbonate; GIBCO BRL, Life Technologies, Woerden, The Netherlands) buffered to pH 7.0 with 0.165 morpholinepropanesulfonic acid (SigmaAldrich Chemie GmbH, Steinheim, Germany). The test was performed in 96-well flat-bottom microtitration plates, which were kept at Ϫ70°C until the day of testing. Each suspension of spores was diluted 1:50 in RPMI 1640 medium to obtain two times the desired inoculum.
Growth was graded on a scale from 0 to 4, as follows: 4 indicated no reduction in growth, 3 indicated a 25% reduction of growth, 2 indicated a 50% reduction of growth, 1 indicated a 75% reduction of growth, and 0 indicated an optically clear well. The MIC endpoint was defined as the lowest concentration of the drugs (alone or in combination) showing 50% inhibition of growth compared with that of the drug-free control (MIC-2). After agitation, the plates were incubated at 35°C for 48 h, after which the optical density (OD) was measured with a spectrophotometer (MS2 reader, Titertek-plus; ICN Biomedical Ltd., Basingstoke, United Kingdom) at 405 nm. The OD of the blank, to which a conidium-free inoculum had been added, was subtracted from the OD values. The percentage of growth for each well was calculated by comparing the OD of the drug-containing well with that of the drug-free control well.
Drug interactions. The in vitro interactions between ITZ and the blockers were studied by a two-dimensional checkerboard microdilution technique in sterile, 96-well flat-bottom microtitration plates, as described below. Each isolate was tested three times on different days.
(i) Microtitration plate setup. For the combination studies, each drug was first serially diluted twofold in the corresponding solvents and then 100-fold in the medium, according to the dilution scheme of NCCLS for water-insoluble drugs, in order to obtain four times the final concentration. A total of 50 l of each concentration of the azole was added to columns 1 to 10, and then 50 l of each concentration of the corresponding blocker was added to rows A to G. Column 12 was the drug-free well that served as the growth control.
Drug interaction modeling. In order to assess the nature of the in vitro interaction between the drugs, the data obtained were analyzed by using four different models that have successfully been used to characterize antifungal drug interactions (18, 39, 53) . The models were parametric and nonparametric approaches of the following two no-interaction theories: the Loewe additivity and the Bliss independence (BI) theories. In the Loewe additivity theory the concentrations of the drugs, alone or in combination, that produce the same effect are compared, while in the BI-based models, the estimates of the combined effect based on the effects of the individual drugs were compared with those obtained in the experiment.
(i) Loewe additivity. Loewe additivity is described by the following equation: (21) . Off-scale MICs were converted to the next highest or the next lowest doubling concentration. For each data set, ⌺FIC min (where min is minimum) was determined when ⌺FIC max (where max is maximum) was less than 4; otherwise ⌺FIC max was determined (21) .
The interpretation of the FICI was as follows: synergistic effect, FICI Յ 0.5; no interaction, FICI Ͼ 0.5 but Յ 4; and antagonistic effect, FICI Ͼ 4 (44) . In practice, synergy or antagonism calculated in this way is equivalent to a reduction or an increase, respectively, of at least 2 dilutions steps in the MIC of the combination compared to the MICs of the drugs alone.
The fully parametric surface approach described by Greco et al. (18) was used based on the following equation:
where E is the OD (dependent variable) at drug concentrations D A and D B (independent variables); E max is the maximal OD observed for the drug-free control; IC 50,A and IC 50,B are the drug concentrations producing 50% of the E max for drugs A and B, respectively; m A and m B are the slopes of the concentration-effect curves (Hill coefficient) for drugs A and B, respectively; and ␣ is the interaction parameter which describes the nature of the interaction. This model was fitted directly to experimental data (the average OD among the replicates for all concentrations of the two drugs alone or in combination) by a nonweighted, nonlinear regression analysis with the MODLAB program (www.medimatics.nl; MEDIMATICS, Maastricht, The Netherlands). Goodness-of-fit criteria included the 95% confidence interval (CI) of the fitted parameters, R 2 , the sum of squares, correlation and covariance matrices, and the residual plots.
When the parameter ␣ as well as its 95% CI was positive statistically significant, synergy was claimed, while when ␣ as well as its 95% CI was negative statistically, significant antagonism was claimed. In any other case, Loewe additivity was concluded. The additivity surface was simulated by fixing all parameters of the Greco model except ␣ to the values obtained after the model was fitted to experimental data; ␣ was fixed at 0. The fitted experimental surface calculated by the Greco model was then subtracted from the additivity surface calculated as described above.
(ii) BI. BI is described by the equation
, where I i is the predicted percentage of inhibition of the theoretical combination of drugs A and B, and I A and I B are the experimental percentages of inhibition of each drug acting alone, respectively. Since I is equal to 1 Ϫ E, where E is the percentage of growth, and by substitution into the former equation, the following equation is derived: E i ϭ E A ϫ E B , where E i is the predicted percentage of growth of the theoretical combination of drugs A and B, respectively, and E A and E B are the experimental percentages of inhibition and growth of each drug acting alone, respectively. Interaction is described by the difference ⌬E between the predicted and the measured percentages of growth at various concentrations. Because of the nature of the interaction, testing with microtiter plates and a twofold dilution of either drug results in a ⌬E for each drug combination. A surface plot is obtained by use of a three-dimensional plot, with ⌬E depicted on the z axis. By the nonparametric surface approach described by Prichard and colleagues (46, 47) , E A and E B are obtained directly from the experimental data, while by the semiparametric surface approach (14, 18) , these values are derived from fitting of the E max model to the concentration-effect curve for each drug alone. Thus, for the latter approach, E A and E B are obtained by the following equation:
, where E, D, E max , IC 50 , and m are the same parameters for drugs A and B described above. The parameters of the model were obtained by a nonweighted nonlinear regression analysis with GraphPad Prism software (San Diego, Calif.). Data were normalized by using the percentages; and the maximum and the minimum values of the E max model, corresponding to 100% and 0%, respectively, were kept constant. The fit of the model was interpreted by using the run test and the R 2 values. After the E max model was fitted to the data, the parameters generated were used to calculate the no-interaction surface for each replicate separately.
For each combination of two drugs in each of the three independent experiments, the observed OD of growth obtained from the experimental data was subtracted from the predicted OD, calculated as described above for each model. When the average difference as well as its 95% CI among the four replicates was positive, statistically significant synergy was claimed; when the difference as well as its 95% CI was negative, significant antagonism was claimed. In any other case, BI was concluded. The values thus obtained for each combination were used to construct a three-dimensional plot. Peaks above and below the 0 plane indicate synergistic and antagonistic combinations, respectively, while the 0 plane indicates no statistically significant interaction. The contour plots were also constructed in order to visualize the drug concentrations that produce an interaction.
Since the plot shows only the interactions for each separate combination of the concentrations, a value is needed to summarize the interaction surface. This was done by calculating the sums of the percentages of all statistically significant synergistic (⌺SYN) and antagonistic (⌺ANT) interactions. Interactions with Ͻ100% statistically significant interactions were considered weak, interactions with 100 to 200% statistically significant interactions were considered moderate, and interactions with Ͼ200% statistically significant interactions were considered strong, as described previously (39) . In addition, the numbers of statistically significant synergistic and antagonistic combinations among the 96 combinations of drug concentrations tested were calculated for each strain.
RESULTS
The MICs of ITZ, based on a 50% reduction of growth, for C. krusei (ATCC 6815) and C. parapsilosis (ATCC 22019) were 0.5 and 0.25 g/ml, respectively, which are within the reference range for quality control strains for ITZ. No reference range has been established for the other drugs. Nevertheless, none of the blocker drugs alone appeared to be active against the Candida isolates. The final inoculum varied from 1.5 ϫ 10 4 to 4 ϫ 10 4 CFU/ml. The MIC of ITZ ranged from 16 to 32 g/ml for the ITZ-R A. fumigatus isolates and from 0.12 to 0.25 g/ml for the ITZ-S isolates. AMD, AML, LAN, LID, and VER were inactive in vitro against all strains tested. However, NIF and FLU were active against some strains, with geometric mean MICs of 15 g/ml (range, 5 to 80 g/ml) and 51 g/ml (range, 10 to 160 g/ml), respectively.
Drugs in combination. (i) FICI evaluation and BI model. (a) ITZ plus AMD.
ITZ and AMD displayed no interaction against most of the ITZ-S A. fumigatus strains tested but were synergistic against two strains. However, the combination was synergistic against six of the ITZ-R strains, with the FICIs ranging from 0.02 to 1. By the BI method all ITZ-S strains displayed very low percentages of synergistic and antagonistic interactions, ranging between 3.6 and 44.3% and Ϫ1.1 and Ϫ24.6%, respectively. Synergistic interactions predominated against the ITZ-R strains, with from 108 to 1,482% synergistic interactions and Ϫ42.9 to Ϫ7.1% antagonistic interactions (Table 1 and Fig. 1) .
(b) ITZ plus AML. ITZ and AML were synergistic against two ITZ-S A. fumigatus strains, with FICIs ranging from 0.5 to 1, and against five strains by use of the BI model, with variations ranging from 219.16 to 52.7% for synergistic interactions and Ϫ10.6 to Ϫ89.4% for antagonistic interactions. A synergistic interaction against three ITZ-R strains was displayed by use of the FICI and against five isolates by use of the BI model (data not shown).
(c) ITZ plus LAN. The interaction between ITZ and LAN against the ITZ-S A. fumigatus strains was less synergistic than that against the ITZ-R A. fumigatus strains, with FICIs ranging from 0.15 to 0.75; by use of the BI model, the drugs displayed synergistic interactions against only three to seven strains. On the contrary, the combination was more synergistic against the ITZ-R strains by both methods evaluated (Table 2) .
(d) ITZ plus LID. In general, the combination of ITZ and LID displayed no interaction against ITZ-S strains according to the FICIs (range, 0.5 to 1), whereas moderate synergistic interactions were found against the ITZ-R strains according to the FICIs (range, 0.02 to 1) and also when the BI model was used to characterize the interaction (Fig. 2) .
(e) ITZ plus NIF. The combination of ITZ and NIF showed synergistic effects against some ITZ-S isolates by both methods. On the contrary, the combination showed potent synergistic interactions against ITZ-R strains in both models, with (Table 3) . (f) ITZ plus FLU. The combination of ITZ and FLU had a synergistic effect against only three ITZ-R strains, whereas no interaction against the other strains was indicated by use of FICI. In contrast, by use of the BI model, the interactions of the combination varied between synergistic and antagonistic against all the strains, resulting in statistically significant differences (Table 4 and Fig. 1 ).
(g) ITZ plus VER. By use of FICI the combination of ITZ and VER had no interaction against most of the strains. In contrast, by use of the BI model the combination was synergistic against four ITZ-S strains and varied between synergistic and antagonistic against the ITZ-R strains (data no shown).
In general, when conventional antifungal agents were combined with pump blockers, relatively high FICIs (Ͼ0.5) were observed against ITZ-R strains, whereas lower FICIs (0.02 to 1) were found against ITZ-R strains. 
FIG. 2. Comparison of the activities of all drugs against ITZ-S and ITZ-R
A. fumigatus strains by using the BI model.
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By use of the BI model and the assumption of a limit of a 100% interaction, the highest synergistic interaction was observed for ITZ and AMD, followed by ITZ and NIF, against ITZ-R strains. Also, proton pump inhibitors, such as LAN, displayed synergistic interactions with ITZ. Interestingly, FLU displayed both synergistic and antagonistic activities against ITZ-R and ITZ-S strains at the same time (Fig. 1) .
(ii) Greco model. The model failed to fit the data for all combinations tested except ITZ and NIF. The program failed to fit the data in eight cases for ITZ and AMD, 13 cases for ITZ and AML, 10 cases for ITZ and LAN, 10 cases for ITZ and LID, 12 cases for ITZ and FLU, and all cases for ITZ and VER.
In values ranging from 0.06 to 0.98 for ITZ and from Ϫ0.37 to 0.81 for AMD. The program failed to fit the data from all data analyzed for ITZ and AML on seven occasions, with R 2 values ranging from 0.009 to 0.98 for ITZ and from 0.002 to 0.75 for AML. The data could not be fitted for the combination of ITZ and LAN on two occasions, with R 2 values ranging from 0.32 to 0.99 for ITZ and from 0.002 to 0.8 for LAN. In the case of the combination of ITZ and LID, the data could not be fitted on six occasions to obtain the IC 50 
DISCUSSION
Efflux mechanisms have been described in mammalian cells. In particular, the upregulation of P glycoproteins, which belong to METs of the ABC superfamily, is characteristic of cancer cells resistant to cytotoxic agents. Several investigators have reported the inhibition of these proteins with different classes of drugs in multiresistant cancer cells (45) . A similar experimental principle had already been investigated to reverse chloroquine resistance in Plasmodium falciparum (4, 5) or the resistance to quinolone antibiotics in Staphylococcus aureus (27) . The present study sought to investigate the effectiveness of several combinations of ITZ with MET inhibitors and nonantimicrobial membrane-active compounds, such as antiarrhythmic agents and proton pump inhibitors. We observed that some of these compounds exhibit potent antifungal effects when used in combination with ITZ.
AMD is the most complicated antiarrhythmic drug ever discovered. It has a number of electrophysiological effects that probably contribute to its antiarrhythmic effect. The drug is available for both oral and intravenous use. The peak concentration of this drug in plasma is 0.5 to 2.5 g/ml (28), but in its steady state, the partition coefficient has been estimated to be from 100 to greater than 1,000 times higher in tissues relative to that in plasma (38) . It was previously demonstrated (9, 10) that this drug alone has in vitro activity against Aspergillus, Fusarium, Cryptococcus, and Candida. We observed that the combination of this drug with ITZ showed synergistic activity against the ITZ-R strains, independent of the model used to characterize the interaction. There is as yet no explanation why this combination interacts synergistically, but the interaction could be due to the inhibition of major pumps, including efflux pumps or the calmodulin system. The concentration at which the synergistic interaction was observed is achievable in serum and tissues, and no major drug-drug interaction with ITZ has been observed in patients; therefore, the potential of this combination warrants further studies with in vivo models.
AMD, which is widely used clinically for its diuretic effect, has been recognized as a drug that possesses growth-inhibitory activity against bacterial cells (15) (16) (17) .
This agent is an inhibitor of various sodium transporters and is toxic to Schizosaccharomyces pombe at low concentrations (19) . In this study no antifungal activity of this drug alone was observed. Also, no significant interaction between ITZ and AMD against ITZ-S and ITZ-R strains was found.
One new antifungal target could be the fungal plasma membrane H ϩ -ATPase, which is an ATP-dependent proton pump. It plays a critical role in fungal cell physiology by regulating the intracellular pH, maintaining ionic balance, and generating the electrochemical proton gradient necessary for nutrient uptake (49, 50) . The H ϩ -ATPase from Saccharomyces cerevisiae has been shown to be essential by gene-disruption experiments (50) , and it displays a number of biochemical and genetic properties that make it attractive as a drug discovery target (41) . The pumps mentioned above are present also in A. fumigatus (6) . These pumps can be blocked by different compounds, including the novel compound conjugated styryl ketone, which was shown to be active when it was tested against A. fumigatus in vitro and in vivo (34, 35) ; but no drug combination was tested against Aspergillus in those studies. Proton pump inhibitors such as LAN and omeprazole were useful when they were used in combination with amoxicillin or erythromycin against Helicobacter pylori (40) , and clinical evidence also indicates that these combinations are active when they are used against this pathogen in humans (31, 32) . LAN is a novel benzimidazole proton pump inhibitor. Inhibition of C. albicans growth in vitro was demonstrated previously (3). In our study this drug alone was inactive against A. fumigatus, but a synergistic interaction against ITZ-R A. fumigatus strains was observed when it was combined with ITZ.
The mechanism of action of LAN is not clear. However, transmission electron microscopy revealed that exposure of eukaryotic cells to this drug resulted in the formation of free membranous vesicles and collapse of the cell surface structure, suggesting an effect on the cell membrane (22) . These effects could contribute to the observed interaction of LAN and ITZ against ITZ-R A. fumigatus strains, although the explanation for the synergism remains unclear.
NIF, a calcium entry blocker, is used for the treatment of angina pectoris and arterial hypertension. In recent years it was demonstrated that some calmodulin inhibitors such as cyclosporine and tacrolimus exert antifungal activities and potentiate the actions of azoles in vitro and in animal models (33, 36, 37) . Our data suggest a potent synergistic effect of NIF and ITZ against ITZ-R strains at clinically therapeutic levels (2). This effect was also observed against C. albicans when NIF or nimodipine was combined with ketoconazole (29, 30) . This effect can be due to the fact that calcium and its binding protein, calmodulin, are known to modulate proliferation, differentiation, and metabolism in a variety of cell types. Calmodulin is a small acidic Ca 2ϩ binding protein, which is thought to induce intracellular Ca 2ϩ fluxes into cellular responses (8) . The concentration of free intracellular calcium can be increased in eukaryotic cells by opening of the voltage-dependent calcium channels (VDCCs), allowing extracellular Ca 2ϩ to enter the cell. Several chemically distinct classes of organic compounds share the ability to inhibit calcium influx through VDCCs (24) . VDCCs are present in yeasts (7, 23, 54) .
FLU, a phenothiazine neuroleptic, is widely used for the treatment of psychotic illnesses (1) , and when it is used alone it displays activity against C. albicans (20) . Our results suggest VOL. 48, 2004 TREATMENT OF ITZ-RESISTANT A. FUMIGATUS INFECTIONS 1341 that this drug exhibits antifungal activity at high concentrations. In combination with ITZ there is a paradoxical effect, in which the combination showed different interactions. This effect can be explained by the fact that FLU both turns off and induces efflux pumps, especially CDR1 (Candida drug resistance) and CDR2 (20) , at different concentrations. FLU antagonized the activity of ITZ, especially at low concentrations of both drugs (Fig. 1) , an effect that reflects the induction of pumps and the reduction of the activities of the azoles. On the contrary, at high concentrations the antagonistic activity was reproducibly replaced by a synergistic interaction. This effect has also been demonstrated against C. albicans by agar techniques and molecular methods (20) . In this study, the data could not satisfactorily be fitted to the Greco model. This may well be explained by the fact that one of the two drugs in the combinations tested does not follow a sigmoid dose-response, and consequently, the IC 50 and the fit of the data obtained cannot be points, because each drug by itself showed no antifungal effect. In this case nonparametric approaches are more useful.
ITZ is metabolized predominantly by the cytochrome P450 3A4 isoenzyme system; and concomitant administration with dihydropyridines, such as NIF, results in increasing concentrations of these drugs in plasma. Side effects such as edema might occur if appropriate dose adjustments are not made (51) . Concomitant administration of ITZ capsules with proton pump inhibitors may cause reduced concentrations of the azole in plasma because of decreased absorption and may be associated with treatment failure (25) . Administration of the oral solution or intravenous formulation may overcome this problem (26) .
In conclusion, this is the first study in which the activity of ITZ in combination with nonantibacterial membrane-active compounds was investigated against A. fumigatus. Further studies are needed to understand the mechanisms underlying the observed synergistic interaction and are warranted in order to develop new therapeutic strategies for the treatment of invasive aspergillosis.
